Publication

102. LOXL2 in non alcoholic Steatohepatitis (NASH): Insights into fibrosis pathogenesis and therapeutic potential, J R Immanuel, R Kumar, A K Agrahari, S Asthana*, Liver International Communications, 2024

101. Structural insights into trypanosomatid Mnk kinase orthologues (kMnks) suggest altered mechanism in the kinase domain, S Sharma, M Singh, A KChiranjivi, A Dadwal, S Ahmed, S Asthana*, Supratik  Das, International Journal of Biological Macromolecules, 2024

100. In silico strategies to recognize pharmacological constraints contrary to COX-2 and 5-LOX, N Kumari, G Singh, M Singh, S Asthana*, S Wakode, JBSD, 2024

99. Characterization and immunogenicity assessment of MERS-CoV pre-fusion spike trimeric oligomers as vaccine immunogen, R Ahuja, P Vishwakarma, S Raj, V Kumar, R Khatri, B Lohiya, S Saxena, G Kaur, G Singh, S Asthana, S Ahmed, S Samal, Human Vaccines & Immunotherapeutics, 2024.

98. Inhibition of early RNA replication in Chikungunya and Dengue virus by lycorine: in vitro and in silico studies, T Agrawal, G Siddqui, R Dahiya, A Patidar, U Madan, S Das, S Asthana, S Samal, A Awasthi, Biochemical and Biophysical Research Communications, 2024

97. Trypanosomatid DRBD9s (double RNA binding domain protein 9) are likely to be eukaryotic initiation factor 4B (eIF4B) orthologues, A Dadwal, S Sharma, S Asthana, S Das, J. Biosciences, 2024.

96. Conformational dynamics of a nicotinic receptor neurotransmitter binding site, M Singh, DC Indurthi, L Mittal, A Auerbach, S Asthana*, elife, 2024.

95. Polyphosphate Kinase-1 regulates bacterial and host metabolic pathways involved in pathogenesis of Mycobacterium tuberculosis, S Chugh, P Tiwari, C Suri, SK Gupta, P Singh, R Bouzeyen, S Kidwai, M Srivastava, NR Rameshwaram, Y Kumar, S Asthana, R Singh, PNAS, 2024.

94. Identification and structural characterization of a pathogenic ARSA missense variant in two consanguineous families from Jammu and Kashmir (India) with late infantile metachromatic leukodystrophy, YR Mir, AK Agrahari, A Hassan, A Choudhary, S Asthana, AK Taneja, S Nawaz, M Ilyas, C Scotti, RAH Kuchay, Molecular Biology Reports, 2024.

93. In silico analysis and characterization of potential inhibitors of MmaA3, a methoxy mycolic acid synthase from Mycobacterium tuberculosis, B Chaudhary, R Sisodia, D Sarmadhikari, PA Mazumdar, SAsthana*, CMadhurantakam, Journal of Biomolecular Structure and Dynamics, 2024.

92. Hotspot site microenvironment in the deubiquitinase OTUB1 drives its stability and aggregation, S Majumder, M Srivastava, P Alam, S Saha, R Kumari, AK Chand, S Asthana, S Sen, TK Maiti, Journal of Biological Chemistry, 2024.

91. Crystallographic mining driven computer-guided approach to identify the ASK1 inhibitor likely to perturb the catalytic region, M Haider, S Sharma, AK Agrahari, M Dikshit, DP Pathak, S Asthana*,Journal of Biomolecular Structure and Dynamics, 2024

90. Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry, S Sadhu, J Dandotiya, R Dalal, R Khatri, AZ Mykytyn, A Batra, M Kaur, R Chandwaskar, V Singh, A Kamboj, M Srivastava, S Mani, S Asthana, S Samal, ZA Rizvi, DB Salunke, BL Haagmans, A Awasthi, Antiviral research, 2024.

89. Intradermal immunization of soluble Influenza HA derived from a lethal virus induces high magnitude and breadth of antibody responses and provides complete protection in-vivo, S Raj, P Vishwakarma, S Saxena, V Kumar, R Khatri, A Kumar, M Singh, S Mishra, S Asthana, S Ahmed, S Samal, Vaccines, 2024. 

88. Harnessing the druggability at orthosteric and allosteric sites of PD-1 for small molecule discovery by an integrated in silico pipeline, L Mittal, RK Tonk, A Awasthi, S Asthana* Computational Biology and Chemistry, 2023

87. Molecular analysis of dUTPase of Helicobacter pylori for identification of novel inhibitors using in silico studies, R Sisodia, D Sarmadhikari, PA Mazumdar, S Asthana*, C Madhurantakam, Journal of Biomolecular Structure and Dynamics, 2023

86. Lead phytochemicals and marine compounds against ceruloplasmin in cancer targeting, S Arfin, K Agrawal, S Maurya, S Asthana, D Di Silvestre, D Kumar, Journal of Biomolecular Structure and Dynamics, 2023

85. Elevated glycosylation of CD36 in platelets is a risk factor for oxLDL mediated platelet activation in type 2 diabetes, S Agarwal, S Saha, R Ghosh, D Sarmadhikari, S Asthana,TK Maiti, R Khadgawat, P Guchhait, The FEBS Journal, 2023

84. Role of Oxidative Stress in Metabolic Reprogramming of Brain Cancer, K Agrawal, S Asthana, D Kumar, Cancers, 2023

83. Design of 3‐phenylcoumarins and 3‐thienylcoumarins as potent xanthine oxidase inhibitors: synthesis, biological evaluation and docking studies, A Fais, F Pintus, B Era, S Floris, A Kumar, D Sarmadhikari, V Sogos, E Uriarte, S Asthana, M J Matos, ChemMedChem, 2023

82. Non-oncology drug (meticrane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells, Y Wang, A Sharma, F Ge, P Chen, Y Yang, H Liu, H Liu, C Zhao, L Mittal, S Asthana, Ingo GH Schmidt-Wolf, Frontiers in Oncology, 2023.

81. Understanding the role of conserved proline and serine residues in the SARS-CoV-2 spike cleavage sites in the virus entry, fusion, and infectivity, R Khatri, B Lohiya, G Kaur, V Maithil, A Goswami, D Sarmadhikari, S Asthana, S Samal, 3 Biotech, 2023

80. RNA-protein interactome at the Hepatitis E virus internal ribosome entry site, S Kumar, R Verma, S Saha, AK Agrahari, S Shukla, ON Singh, U Berry, Anurag, T K Maiti, S Asthana, CT Ranjith-Kumar, M Surjit, Microbiology Spectrum, 2023

79. S Raj, P Vishwakarma, S Saxena, V Kumar, R Khatri, A Kumar, M Singh, S Mishra, S Asthana, S Ahmed, S Samal, Intradermal Immunization of Soluble Influenza HA Derived from a Lethal Virus Induces High Magnitude and Breadth of Antibody Responses and Provides Complete Protection In Vivo, Vaccines, 2023.

78. M Srivastava, L Mittal, D Sarmadhikari, VK Singh, A Fais, A Kumar, S Asthana*, Template Entrance Channel as Possible Allosteric Inhibition and Resistance Site for Quinolines Tricyclic Derivatives in RNA Dependent RNA Polymerase of Bovine Viral Diarrhea Virus, Pharmaceuticals, 2023.

77. V Yadav, L Mittal, S Paliwal, S Asthana, RK Tonk, Repurposing of Flavonoids as Promising Phytochemicals for the Treatment of Lung Carcinoma, Drug Repurposing for Emerging Infectious Diseases and Cancer, Springer Nature, 2023.

76. D Indurthi, M Singh, S Asthana*, Anthony Auerbach, It is possible to calculate agonist efficiency from receptor structure, Biophysical Journal, 2023.

75. AK Agrahari, M Srivastava, M Singh, S. Asthana*, SARS-CoV-2 envelope protein attain Kac mediated dynamical interaction network to adopt "histone mimic" at BRD4 interface, JBSD, 2023.                

74. A Kumari, L Mittal, M Srivastava, DP Pathak, S Asthana*, Deciphering the structural determinants critical in attaining the FXR partial agonism, ACS J Phys Chem B, 2023.

73. Kumar, S., Sarmah, D T., Asthana S., Chatterjee, S., konnect2prot: A web application to explore the protein properties in a functional protein-protein interaction network. Bioinformatics, 2023.

72. VC Maddipati, L Mittal, J Kaur, Y Rawat, C P Koraboina, S Bhattacharyya, S Asthana*, R Gundla, Discovery of Non-Nucleoside Oxindole Derivatives as Potent Inhibitors against Dengue RNA-Dependent RNA Polymerase, Bioorganic Chemistry, 2023.

71. S. Raj, B. Rathi, P. Mehra, S. Asthana*, D Kumar, Deciphering the Role of c-MET in Metabolic Reprogramming of Head and Neck Squamous Cell Carcinoma via In-Silico Analysis: c-MET in Head and Neck Cancer, Chem Biol Lett, 2023.

70. D Kumar, S Asthana*, Autophagy and Metabolism: Potential Target for Cancer Therapy, Elsevier (book), 2022.

69. S K Prajapat, G Srivastava, S Asthana*, Autophagy and metabolic regulation in cancer and its application in drug discovery, Elsevier, 2022.

68. P Singh, S Rawat, A K Agrahari, M Singh, S Chugh, S Gurcha, A Singh, K Abrahams, G Besra, S Asthana, D Rawat, R Singh, NSC19723, a thiacetazone like benzaldehyde thiosemicarbazone improves the efficacy of TB drugs in vitro and in vivo, Microbiology Spectrum, 2022.

67. Translation of hydroethanolic extract of leaves of Psidium guajava Linn for pediatric non-alcoholic fatty liver disease, R Mathur, P Sharma, J Nair, A Sinha, S Chauhan, H Sharma, T Velpandian, U Das, S Asthana, M Srivastava, R Tripathi, Authorea Preprints, 2022

66. S Maghajothia, L Subramaniana, P Mania, M Singh, DR Iyera, S Sharmac, M Khullarc, SM Victord, S Asthana, AS Mullasari, NR Mahapatra, a common Matrix metalloproteinase 8 promoter haplotype enhances the risk for hypertension via diminished interactions with nuclear factor NF-κBlight chain enhancer of activated B cells, Journal of Hypertension, 2022.

65. M Srivastava, L Mittal, A Kumari, A K Agrahari, M Singh, R Mathur, S Asthana*, Characterizing (un)binding mechanism of USP7 inhibitors to unravel the cause of enhanced binding potencies at allosteric checkpoint, Protein Science, 2022.

64. A K Agrahari, M Dikshit, S Asthana*, crysallographic mining of ASK1 regulators to unravel the intricate PPI interfaces for the discovery of small molecule, Computational and Structural Biotechnology Journal, 2022.

63. S Sharma, R Tyagi, M Srivastava, K Rani, D Kumar, S Asthana*, VS Raj, Identification and validation of potent inhibitor of Escherichia coli DHFR from MMV pathogen box, JBSD, 2022.

62. R Khatri, HA Parray, AK Agrahari, ZA Rizvi, R Kaul, S Raj, S Asthana, S Mani, S Samal, A Awasthi, S Ahmed, Designing and characterization of a SARS-CoV-2 immunogen with receptor binding motif grafted on a protein scaffold: An epitope-focused vaccine approach, International Journal of Biological Macromolecules 209, 1359-1367

61. A Agarwal, MF Alam, B Basu, S Pattanayak, S Asthana, GH Syed, M Kalia, S Vrati, Japanese Encephalitis Virus NS4A Protein Interacts with PTEN-Induced Kinase 1 (PINK1) and Promotes Mitophagy in Infected Cells, Microbiology Spectrum, e00830-22

60. L Mittal, R Tonk, A Awasthi, S Asthana*, Traversing through the Dynamic Protein–Protein Interaction Landscape and Conformational Plasticity of PD-1 for Small-Molecule Discovery, Journal of Medicinal Chemistry 65 (8), 5941-5953

59. R Tyagi, M Srivastava, P Jain, RP Pandey, S Asthana*, D Kumar, VS Raj, Development of potential proteasome inhibitors against Mycobacterium tuberculosis, JBSD, 2022.

58. DA Varma, M Singh, S Wakode, NE Dinesh, S Vinaik, S Asthana*, M Tiwari, Structure-based pharmacophore mapping and virtual screening of natural products to identify polypharmacological inhibitor against c-MET/EGFR/VEGFR-2, JBSD, 2022

57. ZA Rizvi, R Dalal, S Sadhu, A Binayke, J Dandotiya, Y Kumar, T Shrivastava, SK Gupta, S Aggarwal, MR Tripathy, DK Rathore, AK Yadav, GR Medigeshi, AK Pandey, S Samal, S Asthana, A Awasthi, Golden Syrian hamster as a model to study cardiovascular complications associated with SARS-CoV-2 infection, eLife, 2022.

56. N Purushotham, M Singh, B Paramesha, VK, SWakode, SK Banerjee, B Poojary, S Asthana*, Design and synthesis of amino acid derivatives of substituted benzimidazoles and pyrazoles as Sirt1 inhibitors, RSC Advance, 2022.

55. H Khurana, M Srivastava, D Chaudhary, TP Gosain, R Kumari, AC Bean, S Chugh, TK Maiti, CE Stephens, S Asthana*, R Singh, Identification of diphenyl furan derivatives via high throughput and computational studies as ArgA inhibitors of Mycobacterium tuberculosis, International Journal of Biological Macromolecule, 2021.

54. L Mittal, RK Tonk, A Awasthi, S Asthana*, Targeting cryptic-orthosteric site of PD-L1 for inhibitor identification using structure-guided approach, Archives of biochemistry and biophysics, 2021.

53. C Suri, A Awasthi, S Asthana*,Crystallographic landscape provides molecular insights into the modes of action of diverse ROR-γt modulators, Drug discovery today, 2021.

52. A Kumari, L Mittal, M Srivastava, D P Pathak and S Asthana*, Conformational characterization of the co-activator binding site revealed the mechanism to achieve the bioactive state of FXR, Frontiers in molecular bioscience, 2021.

51. M Srivastava, L Mittal, A Kumari and S Asthana*, Molecular dynamics simulations reveal the interaction fingerprint of remdesivir triphosphate pivotal in allosteric regulation of SARS-CoV-2 RdRp, Frontiers in molecular bioscience, 2021

50. R Tyagi, M Srivastava, B Singh, S Sharma, R P Pandey, S Asthana*, D Kumar, and V. Samuel Raj, Identification and validation of potent mycobacterial proteasome inhibitor from enamine library, JBSD, 2021

49. S. Chaudhuri, T Kaur, S Jain, C Sharma, S. Asthana*, A review on genotoxicity in connection to infertility and cancer, Chemico-Biological Interactions, 2021.

48. S Panwar, A Kumari, H Kumar, AK Tiwari, P Tripathi, S Asthana*, Structure-based virtual screening, molecular dynamics simulation, and in vitro 2 evaluation to identify inhibitors against NAMPT JBSD. 2021.

47. PP Sharma, S Kumar, S Srivastava, M Srivastava, B Jee, N Yu. Gorobets, D Kumar, M Kumar, S Asthana, P Zhang, Poonam, M Zoltner, B Rathi, Computational Study of Novel inhibitory molecule, 1-(4-((2S,3S)-3-amino-2-hydroxy-4-phenylbutyl)piperazin-1-yl)-3-phenylurea, with high potential to competitively block ATP binding to the RNA dependent RNA polymerase of SARS-CoV-2 virus JBSD, 2021

46. A Kumari, L Mittal, M Srivastava, S Asthana* Binding mode characterization of 13b in the monomeric and dimeric states of SARS-CoV-2 main protease using molecular dynamics simulations, JBSD, 2021

45. V Chandel, PP Sharma, SA. Nayar, S Asthana*, B Rathi, D Kumar, in silico Drug Designing for Head and Neck Cancer Through Targeting Monocarboxylate Transporter 1 and ATP Synthase JBSD, 2021

44. M Singh, M Srivastava, S Wakode; S Asthana*, Elucidation of structural determinants delineates the residues playing key role in differential dynamics and selective inhibition of Sirt1-3, ACS Journal of Chemical Information and Modeling, 2021. 

43. L Mittal, M Srivastava, A Kumari, RK Tonk, A Awasthi, S Asthana*, Interplay among Structural Stability, Plasticity, and Energetics Determined by Conformational Attuning of Flexible Loops in PD-1, ACS Journal of Chemical Information and Modeling, 2021

42. RM Borkar, G. Shankar, SA Mohammed, M Srivastava, VG Reddy, A Kamal, S Asthana, SK. Banerjee, R Srinivas, Identification and characterization of in vitro and in vivo fidarestat metabolites: Toxicity and efficacy evaluation of metabolites, Journal of Mass Spectrometry, 2021

41. A Kumar, R Singh, J Kaur, S Pandey, V Sharma, S Mani, S Asthana, TK Sharma, S Chaudhuri, S Bhattacharyya, N Kumar, Wuhan to World: The COVID-19 Pandemic, Frontiers in Microbiology, 2021.

40. R Sarkar, KB Sharma, A Kumari, S Asthana, M Kalia, Japanese encephalitis virus capsid protein interacts with non-lipidated MAP1LC3 on replication membranes and lipid droplets, Journal of General virology, 2020 

39. R Tyagi, M Srivastava, B Singh, RP Pandey, G Das, S Asthana*, D Kumar, VS Raj, Development of potential proteasome inhibitors against Mycobacterium tuberculosis, JBSD, 2020. 

38. C L Meena, P Singh, R P Shaliwal, V Kumar, A Kumar, A K Tiwari, S Asthana, R Singh, D Mahajan, Synthesis and evaluation of thiophene based small molecules as potent inhibitors of Mycobacterium tuberculosis, European Journal of Medicinal Chemistry, 2020

37. VC Maddipati, L Mittal, M Mantipally, S Asthana, S Bhattacharyya, R Gundla, A Review on the Progress and Prospects of Dengue Drug Discovery Targeting NS5 RNA-Dependent RNA Polymerase, Current Pharmaceutical Design, 2020 

36. S Raj, V Chandel, A Kumar, KK Kesari, S Asthana, J Ruokolainen, M A Kamal, D Kumar, 5 August, Life Sciences, Molecular mechanisms of interplay between autophagy and metabolism in cancer, 2020. 

35. HA Parray, A Chiranjivi, S Asthana, N Yadav, T Srivastava, S Mani, C Sharma, P Vishwakarma, S Das, K Pindari, S Sinha, S Samal, S Ahmed, R Kumar, A human monoclonal antibody targeting receptor binding domain of SARS-CoV-2 isolated using human naïve semi-synthetic phage library, JBC, 2020.

34. SK Thakur, K Goswami, P Rao, S Kaushik, B P Singh, P Kain, S Asthana, S Bhattacharjee, P Guchhait, S V Eswaran, Fluoresceinated Aminohexanol Tethered Inositol Hexakisphosphate: Studies on Arabidopsis thaliana and Drosophila melanogaster and Docking with 2P1M Receptor, ACS Omega, 2020. 

33. L. Mittal, A. Kumari, M Srivastava, M. Singh and S. Asthana*, Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach, JBSD, 2020. 

32. V Chandel, M Srivastava, A Srivastava, S. Asthana*, D Kumar, In-silico interactions of active Phytochemicals with c-MYC EGFR and ERBB2 oncoproteins, chemical biology letters, 2020 

31. M Singh, M Srivastava, N Purushotham, B Paramesha, SR Wakode, SK Banerjee, S. Asthana*, Molecular Dynamics Simulation Reveals New Pocket for the Design of Novel Amino Acid Coupled Sirt1 Selective Inhibitor, Biophysical Journal, 2020. 

30. A Kumari, DP Pathak, S Asthana*, Targeting bile acids for FXR and FATP5 modulation to maintain the lipid homeostasis, International Journal of Biological Sciences, 2020. 

29. S Roy, R Goel, S Aggarwal, S Asthana, A K Yadav, A Awasthi, Proteome analysis revealed the essential functions of PP2A in the induction of Th9 cells, Scientific Report, 2020 

28. N Sugandha, L Mittal, A Awasthi, S. Asthana*, Recent advances of Drug Development in Cancer Metabolism, Cancer Cell Metabolism: A Potential Target for Cancer Therapy, Springer Nature.

27. A Sharma, N Osato, H Liu, S Asthana, TC Dakal, G Ambrosini, P Bucher, I Schmitt, U Wüllner, Common genetic variants associated with Parkinson’s disease display widespread signature of epigenetic plasticity, Scientific Report, 2019.

26. S Saxena, A Chakraborty, M Kaushal, RS Mohil, AK Mishra, LC Singh, J Sharma, A Bansal, U Agrawal, J Mehta, S Asthana, A C Kataki, S Kapur, D Bhatnagar, Breast Cancer in Indian Women: Genetic Risk Factors and Predictive Biomarkers, Annals of the National Academy of Medical Sciences (India), 2019.

25. S. Roy, S. Roy, M. Kar, A. Chakraborty, A. Kumar, F. Delogu, S. Asthana, MP Hande, Combined treatment with cisplatin and tankyrase inhibitor, XAV-939 increases cytotoxicity, abrogates cancer stem-like cells phenotype and increases chemosensitivity of head and neck squamous cell carcinoma cells, Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2019

24. L. Subramanian, S Maghajothi, M Singh, K. Kesh, K Ananthamohan, S Sharma, M Khullar, S M Victor, S Swarnakar, S Asthana, A S Mullasari, N R Mahapatra, A common tag nucleotide variant in MMP7 promoter increases risk for hypertension via enhanced interactions with CREB transcription factor, Hypertension, 2019. Featured as lead article in genetics section of the journal. 

23. M Srivastava, C Suri, S Asthana* What Modulates the Usp7 Function, A Dynamic Pocket or Inter-Regulatory Domains? Biophysical Journal 116 (3), 340a-341a, 2019. 

22. SK Thakur, M. Srivastava, A. Kumar, R. Goel, S. Asthana, SV Eswaran, A Multidimensional Approach to Explore the Use of a Small Hetero-bifunctional Crosslinker based on a Metabolite of the Kynurenine Pathway, Journal of Proteomics and Bioinformatics, 2019. 

21. L. Mittal, M. Srivastava, S. Asthana*, Conformational characterization of Linker underscores the mechanism of cavity formation by 227G in BVDV RdRp, ACS J. Phys Chem B, 2019. 

20. L. Mittal, A. Kumari, C. Suri, S. Bhattacharya, S. Asthana*, Insights into structural dynamics of allosteric non-nucleoside inhibitor binding sites in Hepatitis C Virus RNA-dependent RNA polymerase, Journal of Structural biology and Dynamics, 2019. 

19. Molecular dynamics simulation reveals the possible druggable hot-spots of USP7, Srivastava M, Suri C, Singh M, Mathur R, Asthana S*, Oncotarget. 2018 Sep 28;9(76):34289-34305.

18. Coumarin derivatives as promising xanthine oxidase inhibitors, Fais A, Era B, Asthana S, Sogos V, Medda R, Santana L, Uriarte E, Matos MJ, Delogu F, Kumar A, Int J Biol Macromol. 2018 Dec;120(Pt A):1286-1293.

17. Potent inhibition of hepatitis E virus release by a cyclic peptide inhibitor of the interaction between viral open reading frame 3 protein and host tumor susceptibility gene 101. Anang S, Kaushik N, Hingane S, Kumari A, Gupta J, Asthana S, Shalimar, Nayak B, Ranjith-Kumar CT, Surjit M. J Virol. 2018 Aug 1.

16. Scavenger receptor B type 1: expression, molecular regulation, and cholesterol transport function. Shen WJ, Asthana S, Kraemer FB, Azhar S. J Lipid Res. 2018 Jul;59(7):1114-1131. doi: 10.1194/jlr.R083121. Epub 2018 May 2. 

15. Computational modeling suggests impaired interactions between NKX2.5 and GATA4 in individuals carrying a novel pathogenic D16N NKX2.5 mutation. Mattapally S, Singh M, Murthy KS, Asthana S*, Banerjee SK. Oncotarget. 2018 Feb 9;9(17):13713-13732. doi: 10.18632/oncotarget.24459. eCollection 2018 Mar 2.PMID:29568389

14. Presence of a consensus DNA motif at nearby DNA sequence of the mutation susceptible CG nucleotides. Chowdhury K, Kumar S, Sharma T, Sharma A, Bhagat M, Kamai A, Ford BM, Asthana S*, Mandal CC.Gene. 2018 Jan 10;639:85-95. doi: 10.1016/j.gene.2017.10.001. Epub 2017 Oct 3.PMID:28986316

13. A novel STK1-targeted small-molecule as an "antibiotic resistance breaker" against multidrug-resistant Staphylococcus aureus. Kant S, Asthana S, Missiakas D, Pancholi V. Sci Rep. 2017 Jul 11;7(1):5067. doi: 10.1038/s41598-017-05314-z.PMID:28698584

12. S Aggarwal, M Kandpal, S Asthana, AKYadav. Perturbed Signaling and Role of Posttranslational Modifications in Cancer Drug Resistance. Drug Resistance in Bacteria, Fungi, Malaria, and Cancer (2017, SpringerNature)

11. D Singla, R Bishnoi, SK Dhanda, S Asthana*, Drug transporters as therapeutic targets: Computational models, challenges, and future perspective. Springer Integrative Biotechnology, (2017, Accepted, Springer).

10. Protein Kinase C mediated Sodium Glucose transporter 1 activation in precondition induced cardio protection, A. Kanwal, S Kasetti, U K Putcha, S. Asthana*, SK Banerjee, Drug Design, Development and Therapy. 

9. Structural Docking and Molecular Dynamic Studies to Decipher the Cryptic Role of Fusarium mangiferae in Mango Malformation, S Asthana*, A. Yadav, U. Kalidindi, B Singh, P Jayaswal, 2017 . 

8. Structure/activity relationship of various hydroxycoumarins (Ar- and non-Ar-hydroxylated) and mushroom tyrosinas. S Asthana, P Zucca, A V Vargiu, E Sanjust, P Ruggerone, A Rescigno, ACS Agricultural and Food Chemistry, 2015. 

7. A Molecular analysis provides novel insights into androgen receptor signaling in breast cancer, J Mehta, S Asthana, C C Mandal, S Saxena, Plos One, 2015.

6. Molecular mechanism of BVDV resistance to a potent benzimidazole NNI unveiled by molecular simulations, S Asthana, S Shukla, P Ruggerone, AV Vargiu, ACS Biochemistry, 2014, 53 (44), 6941–6953. 

5. Metabolomics analysis and modeling suggest lysophosphocholines-PAF Receptor interaction in fibromyalgia, L Atzori, PL Caboni, B Liori, A Kumar, M L Santoru, S Asthana, E Pieroni, A Fais, B Era, E Cacace, V Ruggiero, Plos one, 2014 9(9): e107626.

4. Different Molecular Mechanisms of Inhibition of Bovine Viral Diarrhea Virus and Hepatitis C Virus RNA-Dependent RNA Polymerases by a Novel Benzimidazole, S Asthana*, S Shukla, AV Vargiu, M Ceccarelli, P Ruggerone, G Paglietti, ME Marongiu, S Blois, G Giliberti, P La Colla, ACS Biochemistry, 2013, 52 (21), 3752-3764. This work was considered as break through work by World Biomedical Frontiers http://biomedfrontiers.org/infection-2013-11-38/ (World Biomedical Frontiers is dedicated to being on the lookout for biomedical breakthroughs that embody exploration, innovation and significant promise for pharmaceutical development).

3. Different Molecular Mechanisms of Inhibition of Bovine Viral Diarrhea Virus and Hepatitis C Virus RNA-Dependent RNA Polymerases by a Novel Benzimidazole, Asthana S*, Shukla S, Vargiu AV, Ceccarelli M, Ruggerone P, Paglietti G, Marongiu ME, Blois S, Giliberti G, La Colla P, World Biomedical frontiers, 2013, ISSN: 2328-0166, 0166 http://biomedfrontiers.org/infection-2013-11-38/ .

2. Point Mutation I261M Affects the Dynamics of BVDV and its Interaction with Benzimidazole Antiviral 227G, S Asthana, S Shukla, P Ruggerone, M Ceccarelli, G Giliberti, P La Colla, Biophysical Journal, 2011, 100 (3), 385-396.

1.Mechanism of Inhibition By, and of Drug Resistance to, a Benzimidazole Inhibitor of the RNA-Dependent RNA Polymerase of Bovine Viral Diarrhoea Virus, SS Pandey$, S Asthana$, P La Colla, AV Vargiu, P Ruggerone, Biophysical Journal, 2012, 102 (3), 453-462. $ Equal contribution. 

> Suruchi Aggarwal, Manu Kandpal, Shailendra Asthana, Amit Kumar Yadav. Perturbed Signaling and Role of Posttranslational Modifications in Cancer Drug Resistance. Drug Resistance in Bacteria, Fungi, Malaria, and Cancer (2017, Springer).

> Deepak Singla, Ritika Bishnoi, Sandeep Kumar Dhanda,Shailendra Asthana, Drug transporters as therapeutic targets: Computational models, challenges, and future perspective. Springer Integrative Biotechnology, (2017, Springer).

> N Sugandha, L Mittal, A Awasthi, S. Asthana*, Recent advances of Drug Development in Cancer Metabolism, Cancer Cell Metabolism: A Potential Target for Cancer Therapy, SpringerNature. ISBN 978-981-15-1990-1

>S. Prajapat, G Srivastava, S Asthana*, Autophagy and metabolic regulation in cancer and its application in drug discovery, Elsevier, 2022

1. ApplicationNo.202211005368on30/01/2022,“Novelcholicacidderivativesforthetreatmentandpreventionof autoimmune diseases and uses thereof” Applicant: THSTI, Inventor: A. Awasthi, D. Salunke, R. Dalal, S.Sadhu,U.Madan,S.Asthana,P.Singla.

2.Application No.202031050500, 20/11/2020, ref. no. I-169-AM/2018-19(VOL)-V/3194/ILS “A novel process for generation of Nitric Oxide by cells in vitro and endogenous induction of Nitric Oxide in vivo and blockade of Endotoxemia ”B.Ravindran, DKSingh, SAsthana, S.Gaikwad, D.Vasudeven and N.acharya (US and Europe)

3. Application No. 201711009180, 16/03/2017, “Novel Molecules and their HIV Inhibitory Activity” (IPA0336CA/jk),K.Rao,D.Mahajan,S.Asthana,S.Jamwal,S.Khan,D.Mitra.

4. Application No. 201711031441 on 05/08/2017, “Novel Molecules for Liver Disorder”, Applicant: THSTI,Inventor:K.Rao,D.Mahajan,S.Asthana,S.Jamwal,S.Khan.

5.Application No. 201811032275 on 29/08/2018, “A pharmaceutical composition for the treatment of Th17 cells mediated autoimmune inflammatory diseases and uses thereof” Applicant:THSTI,Inventor:A.Awasthi, Z.A.Rizvi, A.Pandey, S.Asthana, C.Suri, K.Srikanth.

6. Application No.202011005512 on 07/02/2020“ Amino acid derived 5-pyrazolyl methyl idenerhodaninecarboxylic acids as selective Sirtuin-1 lysine deacetylase inhibitors” S.Asthana, B.Poojaey,SKBanerjee,N.Purushotham,M. Singh,B.ParameshaandM.Srivastava.

7. Application No. 202011005513 on 07/02/2020, “1,2-Disubstituted benzimidazolyl amino acids as selectiveSirtuin-1 lysine deacetylase inhibitors, S.Asthana, B Poojare, S Banerjee, N. Purushotham, M. Singh, B.ParameshaandM.Srivastava.

8. Application No. 201911053300 on 21/12/2019, “Design, Synthesis of novel oxyindole inhibitors of DENVRNAdependentandRNA polymerase,RGundla, S.Asthana, SBhattacharya, VNaryana, LMittal

9. Application No.202011007117,19/02/2020,m-Torindependent autophagy inducing small peptide andtherapeutic uses thereof, S. Asthana, C. Suri, M. Kalia, A. Awasthi, A Chande, AB Rohde, S Prajapati, S.Shadhu,R.Dalal, V.Bhardwaj and D.Ojha(US patent).

Copy-rights :

1. DiaryNo.:52951/2014-CO/SW, IndianCopyrightDairy No.:14303/2020-CO/SW, Filed:26thSeptember2020

Title:“konnect2prot”

Authors:SamratChatterjee,ShailendraAsthana,Dipanka TanuSarmah,ShivamKumar,EkantSharma,KomalSharmaKrishan

IPRProtectionStatus: Copyright protectionopted[ComputerSoftware]

AdvantageousFeature(s):Konnet2protprovides protein-proteininteraction(PPI)relatedatmostinformationatoneplatform

Application(s):Web-servercanbeusedtoextract protein-proteininteractionrelatedinformation

Subscription: THSTI

2. Title:Mapping of natural variants into secondary structure of human proteins of uniport database, Authors:Ashish K Agrahari,ShailendraAsthan, IPRProtectionStatus: Copyright protectionopted[ComputerSoftware, Application(s):Softwarecanbeusedtoextract secondary structure and unstructured/structured information, Subscription: THSTI

MK Bhan Fellowship:

1. Exploring selective ASK-1 interactome for the discovery of small molecule against NASH: a PPI driven advanced computational approach.

2. Designing small molecule protein-protein interaction inhibitors of CD47-SIRPα and immune checkpoints for the development of immunotherapeutic agents against triple negative breast cancer

DBT funded projects:

3. IdentificationandcharacterizationofsmallmoleculestoblockPD-1/PD-L1pathway inimmunotherapy (DBT-NER).

4. Determine wheather IRGM is a novel therapeutic target for inducing broad spectrumantiviralimmunity (Co-PI)

5. Structural discovery of modulating mechanism of various known immune checkpoints-monoclonal antibodies interacting interfaces for small molecule identification (Co-PI).

6. Improving the resolution of protein-protein interaction (PPI) networks (Co-PI).

7. Identification of lead molecules for development of novel therapeutic strategies against viruses (DBT-NNP).

8. Identification of small molecule inhibitors of PF4 and CXCR3 to prevent Dengue and JEV infection in host (Co-PI).

9. Development and PoC validation of a novel approach to treat HIV infection by anti-viral activity with stimulation of host cell innate immunity (DBT-BIRAC, Co-PI)

DST:

10. Functional characterization of finger loop with/without inhibitors in HCV RNA-Dependent RNA Polymerase:A microscopic picture through Computational approaches (SERB).

11. Towards development of a potent antiviral against the SARS-CoV-2 by targeting the interaction between nucleocapsid protein and viralRNA (Co-PI)

ICMR:

12. Understanding and targeting in organic polyphosphate regulated metabolic pathways in Mycobacterium tuberculosis (Co-PI).

13. Investigating the severity of dengue infection in diabetes  (Co-PI).

14. Small molecules inhibitor of human IRGM as abroad anti-viral agent: a preclinical Study.

15. Establishment of center for advanced research for rapid development of host-directed broad antivirals. 

1.     2015 – CBCADD, Young Investigator Award, IITG.

2.     2015 – DST-SERB Early Career Young Scientist Award.

3.     2012 – International Young Scientist Grant, Regione della sardigna, Italy.

4.     2011 – Young Investigator Best Poster Award, WATOC, Spain.

5.     2011 - Young Researcher Travel grant from the Federation of European Biochemical Societies (FEBS).

6.     2011 – Young Researcher Award, Italian Society of Virology (SIV), Rome.

7.     2010 – CECAM Young Scientist Travel Grant, Italy.

8.     2010 – EMBO Young Scientist Travel Grant, France.

9.     2008 – Young Researcher Travel Grant, University of Redbound, Holland.

10.  2008 – UNICA PhD Grant, University of Cagliari, Italy.

11.  2006 – Selected as young Indian researcher in International MIUR fellowship, Italian Gov. of Science and Technology, Ministry of Science and Education, Italy, 2006 to 2008.

12.  2005- IARI-SRF

13. 2000- Gold Medal, BSc, VBS Purvanchal University.

https://scholar.google.com/citations?hl=en&user=SIyO__QAAAAJ&view_op=list_works&sortby=pubdate

Dr. Kiran Bharat Lokhande (JRS)

Dr. Dhani Ram Mahato (PRS II)

Dr. Meenakshi Varma (PRS I)

Dr. Ashish Kumar Agrahari (MK Bhan Fellow)

Mr. Debapriyo Sarmadhikari (Ph.D. Scholar)

Mr. Gagandeep Singh (Ph.D. Scholar)

Mr. Mohit Pareek (Project Associate I)

Ms. Ridhima Dahiya (Project Associate II)

Mr. Abhishek Choudhary (Project Associate I)

Mr. Sagnik (Masters Trainee)

Ms. Megha (Masters Trainee)

Alumni:

Dr. Charu Suri (Post-doc)

Dr. Mitul Srivasata (PhD student)

Dr. Mrityunjay Singh (PhD student)

Dr. Lovika Mittal (PhD student)

Dr. Anita Kumari (PhD student)

Dr. Shilpa Sharma (Post-doc)